Cyclophosphamide treatment regulates the balance of functional/exhausted tumor-specific CD8+ T cells

Continuous Effector CD8 + T Cell Production in a Controlled Persistent Infection Is Sustained by a Proliferative Intermediate Population

(2016) H. Hamlet Chu et al.   IMMUNITY

The host STING pathway at the interface of cancer and immunity

(2016) Leticia Corrales et al.   JOURNAL OF CLINICAL INVESTIGATION

L’immunothérapie au service de la chimiothérapie, de nouvelles avancées

(2016) Aurélie Hanoteau et al.   M S-MEDECINE SCIENCES

Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients

(2016) Alena Gros et al.   NATURE MEDICINE

Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade

(2016) K. E. Pauken et al.   SCIENCE

T Cell Help Amplifies Innate Signals in CD8 + DCs for Optimal CD8 + T Cell Priming

(2016) Marie Greyer et al.   Cell Reports

Old-School Chemotherapy in Immunotherapeutic Combination in Cancer, A Low-cost Drug Repurposed

(2016) R. Abu Eid et al.   Cancer Immunology Research

Chemotherapy and immunotherapy: A close interplay to fight cancer?

(2016) Aurélie Hanoteau et al.   OncoImmunology

Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents

(2015) Lorenzo Galluzzi et al.   CANCER CELL

Genetic absence of PD-1 promotes accumulation of terminally differentiated exhausted CD8+T cells

(2015) Pamela M. Odorizzi et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

(2015) N. A. Rizvi et al.   SCIENCE

Situational aldehyde dehydrogenase expression by regulatory T cells may explain the contextual duality of cyclophosphamide as both a pro-inflammatory and tolerogenic agent

(2015) Christopher G Kanakry et al.   OncoImmunology

Consensus nomenclature for CD8+T cell phenotypes in cancer

(2015) Lionel Apetoh et al.   OncoImmunology

Effector-like CD8+ T Cells in the Memory Population Mediate Potent Protective Immunity

(2013) Janelle A. Olson et al.   IMMUNITY

Cyclophosphamide treatment induces rejection of established P815 mastocytoma by enhancing CD4 priming and intratumoral infiltration of P1E/H-2Kd-specific CD8+T cells

(2013) Gwendoline Rahir et al.   INTERNATIONAL JOURNAL OF CANCER

Prognostic and Predictive Impact of Intra- and Peritumoral Immune Infiltrates

(2011) W. H. Fridman et al.   CANCER RESEARCH

Type-I IFN drives the differentiation of short-lived effector CD8+T cells in vivo

(2011) Melanie Wiesel et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Host type I IFN signals are required for antitumor CD8+T cell responses through CD8α+dendritic cells

(2011) Mercedes B. Fuertes et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Cyclophosphamide Synergizes with Type I Interferons through Systemic Dendritic Cell Reactivation and Induction of Immunogenic Tumor Apoptosis

(2010) G. Schiavoni et al.   CANCER RESEARCH

KLRG1 signaling induces defective Akt (ser473) phosphorylation and proliferative dysfunction of highly differentiated CD8+ T cells

(2009) S. M. Henson et al.   BLOOD

Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired

(2009) M. Ahmadzadeh et al.   BLOOD

Chemokine Expression in Melanoma Metastases Associated with CD8+ T-Cell Recruitment

(2009) H. Harlin et al.   CANCER RESEARCH

Tumor-Associated Lymphocytes As an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer

(2009) Carsten Denkert et al.   JOURNAL OF CLINICAL ONCOLOGY

Runx3 and T-box proteins cooperate to establish the transcriptional program of effector CTLs

(2009) Fernando Cruz-Guilloty et al.   JOURNAL OF EXPERIMENTAL MEDICINE

IFN-  Enhances Peptide Vaccine-Induced CD8+ T Cell Numbers, Effector Function, and Antitumor Activity

(2009) A. G. Sikora et al.   JOURNAL OF IMMUNOLOGY

Functional and genomic profiling of effector CD8 T cell subsets with distinct memory fates

(2008) Surojit Sarkar et al.   JOURNAL OF EXPERIMENTAL MEDICINE